Furthermore, Robertson et al. demonstrated that treating breast cancer patients with AZD5363 reduced p-Akt/mTOR expression, leading to a decrease in oestrogen receptor-mediated transcription as the primary chemotherapy strategy for breast cancer [20]. Here, MTOR is linked to breast cancer.